Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Foster & Motley Inc.

Foster & Motley Inc. cut its position in Becton, Dickinson and Company (NYSE:BDX) by 7.3% in the third quarter, Holdings Channel reports. The firm owned 8,343 shares of the medical instruments supplier’s stock after selling 654 shares during the period. Foster & Motley Inc.’s holdings in Becton, Dickinson and Company were worth $2,011,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company in the 3rd quarter valued at $26,000. Sound Income Strategies LLC raised its holdings in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company during the second quarter worth about $45,000. Abound Wealth Management grew its holdings in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 96 shares during the last quarter. Finally, Chilton Capital Management LLC increased its position in Becton, Dickinson and Company by 1,233.3% in the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 185 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $240.10 on Thursday. The business has a 50 day moving average price of $237.53 and a 200 day moving average price of $235.16. The company has a market capitalization of $69.40 billion, a P/E ratio of 49.40, a PEG ratio of 1.76 and a beta of 0.43. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $259.33. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BDX shares. Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.